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Visualizing hypoxic tumor
regions is important for
improving cancer treatment,
and hypoxia positron emis-
sion tomography has been
shown to be a promising
tool. The tumor uptake of 3
clinical hypoxia PET tracers,
[18F]FMISO, [18F]FAZA,
and [18F]HX4, was assessed
in a preclinical tumor model
to compare their perfor-
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http://dx.doi.org/10.1016/j.ijrobp.2014.09.045Purpose: Several individual clinical and preclinical studies have shown the possibility
of evaluating tumor hypoxia by using noninvasive positron emission tomography
(PET). The current study compared 3 hypoxia PET tracers frequently used in the
clinic, [18F]FMISO, [18F]FAZA, and [18F]HX4, in a preclinical tumor model. Tracer
uptake was evaluated for the optimal time point for imaging, tumor-to-blood ratios
(TBR), spatial reproducibility, and sensitivity to oxygen modification.
Methods and Materials: PET/computed tomography (CT) images of rhabdomyosar-
coma R1-bearing WAG/Rij rats were acquired at multiple time points post injection
(p.i.) with one of the hypoxia tracers. TBR values were calculated, and reproducibility
was investigated by voxel-to-voxel analysis, represented as correlation coefficients (R)
or Dice similarity coefficient of the high-uptake volume. Tumor oxygen modifications
were induced by exposure to either carbogen/nicotinamide treatment or 7% oxygen
breathing.
Results: TBR was stabilized and maximal at 2 hours p.i. for [18F]FAZA (4.0  0.5)
and at 3 hours p.i. for [18F]HX4 (7.2  0.7), whereas [18F]FMISO showed a constant
increasing TBR (9.0  0.8 at 6 hours p.i.). High spatial reproducibility was observed
by voxel-to-voxel comparisons and Dice similarity coefficient calculations on the 30%Sc, Department of Radi-
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study provides insights into
the strengths and weaknesses
of these tracers.highest uptake volume for both [18F]FMISO (RZ 0.86; Dice coefficientZ 0.76) and
[18F]HX4 (R Z 0.76; Dice coefficient Z 0.70), whereas [18F]FAZA was less repro-
ducible (RZ 0.52; Dice coefficientZ 0.49). Modifying the hypoxic fraction resulted
in enhanced mean standardized uptake values for both [18F]HX4 and [18F]FAZA upon
7% oxygen breathing. Only [18F]FMISO uptake was found to be reversible upon expo-
sure to nicotinamide and carbogen.
Conclusions: This study indicates that each tracer has its own strengths and, depending
on the question to be answered, a different tracer can be put forward. 2015Elsevier Inc.Introduction
Tumor hypoxia is an important factor in worsening cancer
patients’ treatment outcome. Regions of low oxygen
concentration are a well-known characteristic of solid
tumors and can be caused by impaired blood vessel
development, temporal occlusions of blood vessels, or
excessive tumor growth (1, 2). Knowledge of the exten-
sion and location of hypoxia would provide additional
information that could be integrated into strategies of
conventional treatments, potentially leading to improved
therapeutic outcome (3). Positron emission tomography
(PET) has been shown to be a suitable, noninvasive,
3-dimensional imaging technique for the detection of
hypoxic tumor regions. PET tracers containing the
oxygen-sensitive nitroimidazole group are specifically
designed to detect hypoxic regions, and the feasibility of
these tracers has been studied extensively in several in-
dependent clinical and preclinical studies (1).
18F-labeled fluoromisonidazole ([18F]FMISO) was the
first specific hypoxia PET tracer and, although it may
be the most frequently used tracer for this purpose, its suit-
ability is limited because of slow tumor-specific accumula-
tion and nonspecific washout (4). Second-generation
2-nitroimidazole tracers with different clearance and hydro-
philicity characteristics have been developed in an attempt to
overcome these disadvantages, [18F]fluoroazomycin arabi-
noside (FAZA), [18F]fluoroerythronitroimidazole (FET-
NIM), and [18F]tri-fluoroetanidazole. In preclinical settings,
these tracers have been investigated separately or solely in
comparison to hypoxia immunohistochemical staining or
[18F]FMISO PET imaging, using different experimental set-
ups, tumor models, and acquisition protocols (5-8). Next,
the third-generation hypoxia tracer [18F]flortanidazole (HX4)
was developed and evaluated in a preclinical rhabdomyo-
sarcoma tumormodel, where it was found to be dependent on
tumoral oxygenation status (9). Only recently, a comparative
study in preclinical animal models reported a clear relation-
ship among the uptake of [18F]FMISO, [18F]FAZA, and [18F]
HX4 and with immunohistochemical staining for perfusion,
hypoxia, and carbonic anhydrase IX (10). With respect to
usage of PET tumor hypoxia for patient imaging, clinical
studies have indicated that both [18F]FAZA and [18F]FMISO
haveprognostic potential (11, 12), and a phase 1 clinical study
demonstrated that imaging using [18F]HX4 was feasible and
nontoxic (13).In this study, we compared the 3 most frequently used
and clinically available hypoxia tracers, [18F]FMISO,
[18F]FAZA, and [18F]HX4, along with the metabolic tracer
[18F]fluorodeoxyglucose (FDG) in a preclinical tumor
model. We investigated the uptake of each tracer over time
and determined the tumor-to-background ratios. A second
PET scan was performed on the same animal after 48
hours to assess spatial reproducibility. Furthermore, tracer
uptake was challenged by exposing the animals to modi-
fied oxygen concentrations. The focus of this study was to
investigate the performance and characteristics of the
different hypoxia PET tracers, using the same tumor
model.Methods and Materials
Tracer synthesis, tumor model, experimental
design
Tracer synthesis of [18F]FMISO, [18F]FAZA, and [18F]
HX4 (Fig. 1A) was performed as described previously
(14-17). All animal experimental procedures were
approved by the Animal Ethical Committee of Maastricht
University and were in accordance with the Helsinki
Declaration of 1975, as revised in 2000. Adult WAG/Rij
rats received subcutaneous implants of syngeneic rhab-
domyosarcoma R1 tumors (1 mm3) in the lateral flank.
Experiments were started when tumors reached a minimal
volume of 3 cm3 to meet the resolution of the PET scanner
and to have a stable hypoxic (18) and necrotic (5) area.
Average tumor volume for [18F]FDG was 21  12 cm3,
16  6 cm3 for [18F]FAZA, 13  6 cm3 for [18F]FMISO,
and 11  5 cm3 for [18F]HX4. During the experimental
procedures, rats were anesthetized with intraperitoneal
injections of sodium pentobarbital (60 mg/kg). Animals
were immobilized on a board and placed outside the
scanner between scans to maintain and monitor anesthesia.
Radioactive tracers (radiochemical purity was maintained
at >95% and synthesis yield at 5.2  2.5 GBq) were
injected into the lateral tail vein by using an intravenous
line (0.4 mm 27-G Venoflux needle; Vygon Vet, Ecouen,
France) flushed with 10% heparin solution (21  2 MBq
for [18F]FDG, 17  5 MBq for [18F]FAZA, 21  2 MBq
for [18F]FMISO, and 21  2 MBq for [18F]HX4).
Fig. 1. Tracer characteristics and imaging protocols. (A) Structure formula, main clearance system, and logP values for
hydrophilicity of the 3 hypoxia tracers [18F]FMISO, [18F]FAZA, and [18F]HX4 and the metabolic tracer [18F]FDG [9]. (B)
Schematic representation of the different imaging protocols for dynamic imaging and for oxygen modification, using either
nicotinamide combined with carbogen breathing or 7% oxygen breathing. Imaging acquisition is indicated by black boxes.
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Images were acquired and analyzed using a clinical PET/
CT scanner (Siemens Biograph 40; Siemens Healthcare)
and dedicated software (TrueD VC60; Siemens) as
described in more detail in online supplementary material
(available online at www.redjournal.com) and previously
(9). Tumor-to-blood ratios (TBR) and tumor-to-muscle ra-
tios (TMR) were determined using heart and muscle of the
hind leg as background tissue, respectively. Spatial repro-
ducibility scans were performed in the same animal within
short time frames, using rigid registration voxel-to-voxel
analysis (from 2 to 6 hours post injection [p.i.]) or 48
hours apart using nonrigid registration (see supplementary
material; available online at www.redjournal.com) of the
tumor for long-term comparison to overcome the 24%
tumor growth (which were 31%  2% for [18F]FDG, 26%
 2% for [18F]FAZA, 23%  1% for [18F]FMISO, and
22%  3% for [18F]HX4). Furthermore, a voxel-wise
comparison of the 2 scans was performed for which a
correlation coefficient was calculated. Imaging schedules
for oxygen modification using either nicotinamide
(500 mg/kg, intraperitoneal) and carbogen (95% O2, 5%
CO2; flow Z 5 L/min) or 7% oxygen (residual N2 flow Z
2.5 L/min) breathing are shown in Figure 1B. In short, after
injection of the tracer, the first basal scan was performed at2 hours p.i., followed by oxygen modification treatment and
a second scan at 5 hours p.i.
Statistics
Prism version 5.01 software (GraphPad) for Windows
(Microsoft) was used to perform statistical analyses. To
determine the statistical significance of differences between
2 independent groups of variables, we used the nonpara-
metric Mann-Whitney U test for small groups. Spatial
reproducibility was analyzed using either a Dice similarity
coefficient for the calculation of the overlap fractions or
Pearson correlation for voxel comparison. P values of <.05
were assumed to be significant.
Results
PET/CT imaging was performed to assess tracer accumula-
tion over time for the 4 different tracers, using a dynamic
imaging schedule (Fig. 1 A and B). Each tracer had a
different accumulation pattern within the tumor, represented
by maximum (SUVmax; Fig. 2A) and mean (SUVmean;
Fig. E1A; available online at www.redjournal.com) stan-
dardized uptake values, whereas blood and muscle tracer
uptake exhibited similar patterns. Due to clearance of the
Fig. 2. SUVmax and TBR. (A) SUVmax of the tumor (red), blood (blue), and muscle (black) over time. (B [Left]) Maximum
TBR over time for [18F]FDG (red), [18F]FAZA (blue), [18F]FMISO (green), and [18F]HX4 (black). (B [Right]) TBR tracer
comparison at 3 hours p.i. *P<.05, ***P<.001. (C [Left])MaximumTMRover time. (C [Right])MaximumTMRcomparison for
the 4 tracers at 3 hours p.i. Number of animals for all experiments: [18F]FDG nZ12, [18F]FAZA nZ12, [18F]FMISO nZ16, and
[18F]HX4 nZ18 except for Figure C [18F]FAZA nZ12. Data are means  SEM. SUVmaxZ maximum standard uptake value;
TBRZ tumor-to-blood ratio; TMRZ tumor-to-muscle ratio. A color version of this figure is available at www.redjournal.org.
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regions, all TBRs were greater than 1 (Fig. 2B and Fig. E1B;
available online at www.redjournal.com). Furthermore,
clearance rates for heart andmusclewere comparable, giving
a muscle to blood ratio around unity (Fig. E1D; available
online at www.redjournal.com). For the metabolic tracer[18F]FDG, the maximal TBR of 2.4  0.3 was reached at 2
hours p.i. Of all the hypoxia tracers, [18F]FAZAwas the first
to reach a plateau phase for TBR at 2 hours p.i. (4.0  0.5),
followed by [18F]HX4 (7.2  0.7) at 3 hours p.i. (Fig. 2B).
TBR for [18F]FMISO kept increasing; TBR of [18F]FMISO
at 6 hours p.i. was comparable to that of [18F]HX4 at 3 hours
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this tracer had a significantly higher TBR than either
[18F]FAZA (PZ.0154) or [18F]FMISO (P<.0001) (Fig. 2B,
right panel); even at 2 hours p.i., [18F]HX4 had already
reached a TBR that was equal to or higher than that of
[18F]FMISO or [18F]FAZA.When muscle tissue was used as
a reference, trends were shown for the hypoxia tracers that
were similar compared to maximal TBR (Fig. 2C and
Fig. E1C; available online at www.redjournal.com).
Uptake images from 2, 3, 4, and 5 hours p.i. were
compared to the 6-hour p.i. scan to perform a voxel-to-voxel
comparison of absolute tumor uptake. A correlation coeffi-
cient was calculated from the 2 scans (Fig. 3A). Averaged
correlation coefficients demonstrated a stable uptake patternFig. 3. Voxel-to-voxel analysis and spatial reproducibility. (A
between the scan obtained at 2, 3, 4, or 5 hours p.i. and the
Correlation coefficients of voxel-to-voxel analyses over a short-
efficients of voxel-to-voxel analyses over a 48-hour time frame
0.0061, PFAZA vs FMISOZ 0.0003, and PFAZA vs HX4Z 0.0121. E
Representative [18F]HX4 PET/CT image of a tumor cross-sectio
and retest scans shows the 30% of the total tumor volume with th
calculated and represent the Dice similarity coefficient. (E) Spatia
tracer as a percentage of total tumor volume: [18F]FDG nZ4, [18
are means  SEM.in the tumor for all investigated tracers over short time pe-
riods (up to 6 hours) (Fig. 3B). Reproducibility was studied
by comparing 2 PET scans acquired within a 48-hour time
interval using voxel-to-voxel analyses. Calculated correla-
tion coefficients were high for [18F]FDG (0.87), [18F]
FMISO (0.86), and [18F]HX4 (0.76); whereas [18F]FAZA
had a significantly (P<.05) lower correlation coefficient
(0.52) (Fig. 3C). To further investigate spatial reproduc-
ibility, we calculated an overall Dice similarity coefficient in
which the high uptake region as a percentage of the total
tumor volume from the first scan was compared to the same
percentage of total volume area from a second scan
(Fig. 3D). This analysis showed a high reproducibility for
[18F]FDG (0.83), [18F]FMISO (0.85), [18F]HX4 (0.79), and) Dynamic scans were used for voxel-to-voxel comparison
6-hour scan, shown in the representative scatter plot. (B)
term time frame. For all tracers, nZ4. (C) Correlation co-
shows [18F]FAZA is significantly lower: PFDG vs FAZA Z
ach dot represents 1 animal, and the mean is indicated. (D)
n visualized over a 48-hour interval. Delineation on the test
e highest SUV. Overlapping fractions of these regions were
l reproducibility over a 48-hour time frame is presented per
F]FAZA nZ7, [18F]FMISO nZ8, and [18F]HX4 nZ4. Data
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with the highest tracer uptake. However, when only the 10%
highest uptake of the tumor volume was selected, [18F]FDG,
[18F]FMISO, and [18F]HX4 showed high spatial reproduc-
ibility (0.65, 0.59, and 0.49, respectively), whereas [18F]
FAZA showed a significantly lower (P<.05) spatial repro-
ducibility of 0.14 (Fig. 3E).
Rats were exposed to 7% oxygen breathing (Fig. 1B),
mimicking acute hypoxia. The relative SUVmean tracer
uptake after 7% oxygen treatment was significantly
increased for [18F]HX4 (P<.01) and [18F]FAZA (P<.05) inFig. 4. Oxygen modification. Relative SUVmean and tracer rat
oxygen (7% oxygen) (A) and those receiving nicotinamide/ca
compared 5 hours p.i. to 2 hours p.i. (vertical axis: relative SUV)
at 5 hours p.i. compared to 2 hours p.i. *P<.05, **P<.01, ***P<.
FAZA nZ14, [18F]FMISO nZ16, and [18F]HX4 nZ18; for 7%
nZ8, and [18F]HX4 nZ8; for carbo: [18F]FDG nZ8, [18F]FAZA
injection; SUVmax Z maximum standard uptake value; TBR Zthe tumor compared to that in untreated animals (Fig. 4A).
The mean TBR for [18F]FAZA was significantly increased
(P<.05); the mean TMR showed a significant increase for
all 3 hypoxia tracers ([18F]FAZA, P<.01; [18F]FMISO,
P<.05; and [18F]HX4, P<.01) (Fig. 4A). When the effect of
maximal tumor uptake on increased hypoxia was studied,
no significant effects were observed, although there was a
trend toward increased uptake of [18F]HX4 in the tumor
(Fig. E2A; available online at www.redjournal.com).
The reversibility of tracer uptake on tumor reoxygena-
tion was examined by treating the rats with nicotinamideios compare untreated rats (basal) with those breathing 7%
rbogen (carbo) treatment (B). SUVs were calculated and
for each organ separately and for the relative TBR or TMR
001. Data are means  SD for basal: [18F]FDG nZ12, [18F]
oxygen: [18F]FDG nZ7, [18F]FAZA nZ7, [18F]FMISO
nZ8, [18F]FMISO nZ6, and [18F]HX4 nZ14. p.i.Z post
tumor-to-blood ratio; TMR Z tumor-to-muscle ratio.
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available online at www.redjournal.com) indicated that
[18F]FMISO remained stable over time in the baseline sit-
uation, whereas for other tracers uptake decreased. Influ-
encing tumors toward a more oxygenated state only caused
a decrease in [18F]FMISO tumor uptake and did not change
uptake of [18F]HX4 and [18F]FAZA (Fig. 4B). Blood up-
take values increased for [18F]HX4, but uptake in the
muscle was not influenced. Mean TBR and TMR signifi-
cantly decreased for [18F]FMISO, and maximal values
demonstrated comparable results (Fig. E2B; available on-
line at www.redjournal.com).Discussion
This study compared the frequently used hypoxia PET
tracers [18F]FMISO, [18F]FAZA, and [18F]HX4 and the
metabolic tracer [18F]FDG in an animal tumor model to
assess their tumor-to-background ratios, spatial reproduc-
ibility, and sensitivity to oxygen modification.
The rat rhabdomyosarcoma R1 model with a large
hypoxic fraction (18) was chosen to ensure sufficient
visualization of the uptake of hypoxia tracers using a
preclinical model on a clinical PET/CT scanner. Although
some variation in tumor volume was seen, the hypoxic
fraction was shown to be stable within the tumor model
(18). PET acquisition was performed from the time of
injection until 6 hours p.i. to determine the optimal uptake
in the tumor and highest TBR. In this study, we found the
most optimal TBR for [18F]FAZA at 2 hours p.i. This
finding is consistent with clinical studies in head and neck
squamous cell carcinoma and nonesmall-cell lung cancer
(NSCLC), where imaging at 4 hours p.i. did not improve
the TBR compared to 2 hours p.i. (19-21). [18F]HX4
showed an optimal TBR at 3 hours p.i., which was also
observed in an NSCLC patient study where image contrast
did improve from 2 to 4 hours p.i. (22). As clinically
demonstrated, [18F]FMISO does not show plateau forma-
tion and has better TBR at later time points (23), which
was also observed in this preclinical study. Comparative
studies already have indicated that [18F]HX4 imaging in
head and neck cancer patients at 1.5 hours p.i. was found
to have TMR properties similar to those of [18F]FMISO at
2 hours p.i. (24). This is also reflected in the biological
half-life of the tracers, which is much higher in normal
tissue for [18F]FMISO (clinical: 12-13 hours [22]; pre-
clinical: 4.5 hours) than for [18F]HX4 (clinical: 4.3 hours
[22]; preclinical: 2.2 hours) or [18F]FAZA (preclinical: 2.8
hours). The findings from this preclinical study are in line
with those from available clinical studies, and although
caution needs to be taken in extrapolation of the data, this
might indicate that the results found here in this animal
model can be translated to some extent to the clinical
setting.
One disparity between clinical and preclinical studies is
the use of anesthetic drugs. In this study, pentobarbital wasused, and although it was shown that this causes a reduction
in the radioactivity in blood and muscle, it did not influence
tracer uptake in the tumor, nor did it lead to a significant
change in tumor-to-background ratios (25).
The ultimate goal of tumor hypoxia imaging is to
improve treatment outcome either by detecting hypoxia to
aid in the decision to add specific antihypoxia drugs or by
adapting radiation therapy using image guidance. Consid-
ering that hypoxia imaging can be used to generate
personalized intensity modulated radiation therapy plans in
which these radiation-resistant parts of the tumor can be
boosted (26, 27), it would be desirable to have a tracer that
shows stable uptake over time so that a single scan could be
used for several days of treatment. Voxel-to-voxel analyses
resulted in high reproducibility for all tracers within a
6-hour scan. Examining spatial reproducibility by
comparing a high uptake region revealed good overlap
between 2 consecutive scans 48 hours apart for
[18F]FMISO, [18F]HX4, and [18F]FDG. For [18F]FMISO,
this was also reported in a recent clinical head and neck
patient study in which 2 scans were highly reproducible
over 48 hours (28). However, voxel-to-voxel analysis of
[18F]FMISO uptake over a 3-day interval found a correla-
tion of the hypoxic distribution in less than 50% of the head
and neck cancer patients (29). [18F]FMISO in the same
patient population and during chemoradiation therapy
showed a stable conformation of the hypoxic subvolumes
(30). Our data show that reproducibility of [18F]FAZA is
poor after 48 hours, even without additional anticancer
treatment. This is surprising given the fact that all investi-
gated hypoxia tracers are based on the same nitroimidazole
trapping mechanism. Contradictions in [18F]FAZA repro-
ducibility are observed between different preclinical and
clinical studies, which might also be caused by the differ-
ences in metabolism among organisms. Preclinical micro-
PET analysis of [18F]FAZA uptake showed voxel-to-voxel
reproducibility between 2 baseline scans performed 24
hours apart; even after fractionated radiation therapy, a
fairly stable intratumoral tracer distribution was observed
(31). However, in a clinical trial, [18F]FAZA uptake was
evaluated after several rounds of radiation therapy treat-
ment and hypoxic regions were found not to be in the same
location (19). Although [18F]HX4 shows good reproduc-
ibility in first clinical experiments (22), the stability of
[18F]HX4 in detecting the hypoxic fraction during therapy
needs to be further assessed. Uptake of [18F]FDG was
clearly distinguishable from background and was highly
reproducible, demonstrating the outstanding application of
[18F]FDG in the detection of tumors. However, we consider
[18F]FDG to be a metabolic tracer rather than a marker for
hypoxia.
Because tumor hypoxia is a dynamic process that con-
sists of both chronic and acute hypoxia, a tumor’s oxygen
status changes continuously, and most hypoxia tracers
mainly detect the chronic hypoxic fraction. However, there
are suggestions that acute hypoxia also plays a prominent
role in determining the treatment outcome (32). Changing a
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breathing mimics this dynamic process and gives the op-
portunity to study the behavior of tracer uptake under these
conditions. In the ideal situation, one would wish a hypoxia
tracer to rapidly and specifically accumulate in the hypoxic
regions with fast clearance in the nonhypoxic tissues.
Binding of the tracer would be irreversible, and no circu-
lating free available tracer would be present.
Previous studies have shown that a treatment combining
nicotinamide and carbogen increases a tumor’s oxygen
status (9, 33), whereas 7% oxygen breathing increases the
hypoxic fraction (9). In this study, the oxygen modification
was applied only 2.5 hours after tracer injection. Increasing
the hypoxic fraction during tracer accumulation is depen-
dent on the presence of unbound, circulating tracer. For all
hypoxia tracers, circulating tracer was present after 3 hours,
based on the measured activity in the blood (SUVof 2.4 for
[18F]FDG; 0.3 for [18F]FAZA; 0.8 for [18F]FMISO; and 0.3
for [18F]HX4); however only [18F]FAZA and [18F]HX4
showed increased uptake in the tumor after 7% oxygen
breathing. This effect was observed mainly in the mean
values rather than in the maximum values, indicating that
the tumor’s overall oxygenation was altered, whereas the
maximum value is determined by the severe hypoxic re-
gions that will be less affected by this treatment. Exposure
to high oxygen concentrations at 2.5 hours after tracer in-
jection would prevent further accumulation or reverse
tracer binding. For [18F]FAZA, preclinical data are avail-
able that show reduced uptake after pure oxygen or carb-
ogen breathing in tumor-bearing mice (8, 34). In our
experimental setting only [18F]FMISO showed a lower
uptake upon reduced hypoxia. Together with the results of
constant accumulation of [18F]FMISO in the tumor over
time these data suggest that further accumulation is pre-
vented when reducing the hypoxic fraction. Previous
studies observed that [18F]FMISO uptake in squamous cell
carcinoma-bearing mice was influenced by the altered
breathing condition (35). These experiments challenged the
tracers to their limits and tried to mimic the changing ox-
ygen concentrations in a tumor. It must be kept in mind that
these results are influenced by the tumor and animal model
chosen and that the tracer metabolism is different in pa-
tients. Furthermore, exposing animals to modified oxygen
concentration will introduce changes to the whole organism
that might influence the distribution and metabolism of the
tracer. Our data suggest that [18F]HX4 and [18F]FAZA are
more sensitive to acute hypoxia, whereas [18F]FMISO up-
take is influenced by reoxygenation.
Conclusions
In conclusion, all investigated tracers showed different
characteristics. The ultimate hypoxia tracer has not been
developed, but this and other studies show that hypoxia
imaging using the existing tracers gives extra information
that can be very useful in the treatment of cancer patients.References
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